NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $56.84 +0.86 (+1.54%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$56.86 +0.02 (+0.04%) As of 11/13/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$55.81▼$57.2850-Day Range$51.52▼$65.5352-Week Range$25.36▼$66.02Volume558,769 shsAverage Volume794,900 shsMarket Capitalization$2.89 billionP/E Ratio189.47Dividend YieldN/APrice Target$62.30Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation. AtriCure also offers products for managing post-operative pain. Founded in 2000, AtriCure is headquartered in Mason, Ohio, and serves customers in the United States and international markets.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreATRC MarketRank™: 2.70426229508 of 5 starsAtriCure scored higher than 54% of companies evaluated by MarketBeat, and ranked 470th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtriCure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.64% Earnings GrowthEarnings for AtriCure are expected to grow by 13.64% in the coming year, from $0.44 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.40.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 189.47, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.00% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in AtriCure has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.72 News SentimentAtriCure has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AtriCure this week, compared to 4 articles on an average week.Search Interest4 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,172,263.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesAtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street ZenNovember 14 at 1:25 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Atricure (ATRC) and CytomX Therapeutics (CTMX)November 13 at 5:01 PM | theglobeandmail.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 15 at 1:00 AM | Profits Run (Ad)AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference TranscriptNovember 9, 2026 | seekingalpha.comAtriCure: A New Quality Metric Could Put A Clip In Nearly Every SternotomyNovember 7, 2026 | seekingalpha.comAtriCure (NASDAQ:ATRC) Stock: Insider Salvatore Privitera Sells 8,404 SharesNovember 7, 2026 | americanbankingnews.comInsider Selling: AtriCure (NASDAQ:ATRC) Insider Sells 8,404 Shares of StockNovember 6, 2026 | insidertrades.comAtriCure (NASDAQ:ATRC) Sets New 12-Month High Following Earnings BeatNovember 6, 2026 | americanbankingnews.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 at the beginning of 2026. Since then, ATRC stock has increased by 43.7% and is now trading at $56.84. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, November, 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.23. The medical device company earned $154.45 million during the quarter, compared to analysts' expectations of $151.05 million. AtriCure had a trailing twelve-month return on equity of 4.01% and a net margin of 2.52%. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional shareholders of AtriCure include State Street Corp (4.18%), GW&K Investment Management LLC (1.78%), First Eagle Investment Management LLC (0.57%) and Public Sector Pension Investment Board (0.51%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Chevron (CVX), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Verizon Communications (VZ), C3.ai (AI), CVS Health (CVS) and Delta Air Lines (DAL). Company Calendar Last Earnings11/03/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATRC's financial health is in the Green zone, according to TradeSmith. ATRC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,350Year Founded2000Price Target and Rating Average Price Target for AtriCure$62.30 High Price Target$70.00 Low Price Target$44.00 Potential Upside/Downside+9.6%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.30 Trailing P/E Ratio189.47 Forward P/E Ratio113.68 P/E GrowthN/ANet Income-$11.45 million Net Margins2.52% Pretax Margin2.75% Return on Equity4.01% Return on Assets3.03% Debt Debt-to-Equity Ratio0.17 Current Ratio4.33 Quick Ratio3.29 Sales & Book Value Annual Sales$534.53 million Price / Sales5.41 Cash Flow$0.32 per share Price / Cash Flow178.85 Book Value$10.47 per share Price / Book5.43Miscellaneous Outstanding Shares50,920,000Free Float48,885,000Market Cap$2.89 billion OptionableOptionable Beta1.23 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ATRC) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.